ESMO 2021 Solid Tumor – Javier Cortés

Javier Cortés highlights the superiority of trastuzumab deruxtecan compared to trastuzumab emtansine in patients with HER2-positive metastatic breast cancer and the resulting future therapy algorithm, potential combinations in the management of patients with HER2-negative breast cancer and the clinical relevance of immunotherapy-based approaches in the treatment of triple-negative breast cancer.

Here is the full ESMO 2021 Solid Tumors report.